Skip to main content

Bifidobacterium adolescentis CGMCC 15058 alleviates liver injury, enhances the intestinal barrier and modifies the gut microbiota in d-galactosamine-treated rats

  • 2018-10-22
  • Applied Microbiology and Biotechnology 103(1)
    • Yating Li
    • L. Lv
    • Jianzhong Ye
    • D. Fang
    • D. Shi
    • Wen-rui Wu
    • Qing Wang
    • Jingjing Wu
    • Liya Yang
    • Xiaoyuan Bian
    • Xianwan Jiang
    • Huiyong Jiang
    • Ren Yan
    • Conggao Peng
    • Lanjuan Li

Abstract

Acute liver failure is a drastic, unpredictable clinical syndrome with high mortality. Various preventive and adjuvant therapies based on modulating the gut flora have been proposed for hepatic injury. We aimed to explore the preventive and therapeutic effects of Bifidobacterium adolescentis CGMCC15058 on rat liver failure, as well as the potential microecological and immunological mechanisms of those effects. B. adolescentis CGMCC15058 (3 × 109 CFU), isolated from healthy human stool, was gavaged to Sprague-Dawley rats for 14 days. Acute liver injury was induced on the 15th day by intraperitoneal injection of D-galactosamine. After 24 h, liver and terminal ileum histology, liver function, plasma cytokines, bacterial translocation and gut microbiota composition were assessed. We found that pretreatment with B. adolescentis significantly relieved elevated serum levels of alanine aminotransferase (ALT), total bile acid and lipopolysaccharide-binding protein and enhanced the expression of mucin 4 and the tight junction protein zonula occludens-1. B. adolescentis exhibited anti-inflammatory properties as indicated by decreased levels of mTOR and the inflammatory cytokines TNF-α and IL-6, as well as elevated levels of the anti-inflammatory cytokine interleukins-10 in the liver. Similar anti-inflammatory signs were also found in plasma. B. adolescentis significantly altered the microbial community, depleting the common pathogenic taxon Proteus and markedly enriching the taxa Coriobacteriaceae, Bacteroidales and Allobaculum, which are involved in regulating the metabolism of lipids and aromatic amino acids. Our findings not only suggest B. adolescentis acts as a prospective probiotic against liver failure but also provide new insights into the prevention and treatment of liver disease.

Keywords: Acute liver failure; Bifidobacterium adolescentis; D-galactosamine; Gut microbiota.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium adolescentisAlleviated Liver InjuryBeneficial
Large
Bifidobacterium adolescentisAltered Gut Microbiota CompositionBeneficial
Large
Bifidobacterium adolescentisImproved Intestinal Barrier FunctionBeneficial
Moderate
Bifidobacterium adolescentisReduced Inflammation LevelsBeneficial
Moderate
Bifidobacterium adolescentis iVS-1Altered Gut Microbiome CompositionBeneficial
Moderate
Bifidobacterium adolescentis iVS-1Increased Interleukin-10 LevelsBeneficial
Large
Bifidobacterium adolescentis iVS-1Reduced Elevated Serum Alanine Aminotransferase (ALT)Beneficial
Moderate
Bifidobacterium adolescentis iVS-1Reduced Lipopolysaccharide-Binding ProteinBeneficial
Moderate
Bifidobacterium adolescentis iVS-1Reduced Total Bile Acid LevelsBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.